[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

YU61096A - Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije - Google Patents

Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije

Info

Publication number
YU61096A
YU61096A YU61096A YU61096A YU61096A YU 61096 A YU61096 A YU 61096A YU 61096 A YU61096 A YU 61096A YU 61096 A YU61096 A YU 61096A YU 61096 A YU61096 A YU 61096A
Authority
YU
Yugoslavia
Prior art keywords
pharmaceutical formulations
synthesis
novel intermediates
bridged
bridged bisindolylmaleimides
Prior art date
Application number
YU61096A
Other languages
English (en)
Other versions
YU49316B (sh
Inventor
Mary Faul Margaret
Ann Krumrich Christine
Larry Winneroski Leonard
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21725638&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=YU61096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of YU61096A publication Critical patent/YU61096A/sh
Publication of YU49316B publication Critical patent/YU49316B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Ovaj pronalazak izlaže jedinjenja formule Pronalazak dalje izlaže korišćenje ovog jedinjenja za dobijanje N,N'-premoštenih bisihdolimaleimida. Dalje, ovaj pronalazak izlaže farmaceutske formulacije i postupke za njihovo korišćenje u suzbijanju protein kinaze C kod sisara.
YU61096A 1995-11-20 1996-11-18 Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije YU49316B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US734595P 1995-11-20 1995-11-20

Publications (2)

Publication Number Publication Date
YU61096A true YU61096A (sh) 1999-03-04
YU49316B YU49316B (sh) 2005-06-10

Family

ID=21725638

Family Applications (1)

Application Number Title Priority Date Filing Date
YU61096A YU49316B (sh) 1995-11-20 1996-11-18 Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije

Country Status (31)

Country Link
EP (1) EP0776899B1 (sh)
JP (2) JP4100708B2 (sh)
KR (1) KR100342142B1 (sh)
CN (1) CN1066734C (sh)
AR (2) AR004719A1 (sh)
AT (1) ATE191219T1 (sh)
AU (1) AU701659B2 (sh)
BR (1) BR9611709A (sh)
CA (1) CA2237401C (sh)
CO (1) CO4750824A1 (sh)
CZ (1) CZ150398A3 (sh)
DE (1) DE69607443T2 (sh)
DK (1) DK0776899T3 (sh)
EA (1) EA000639B1 (sh)
ES (1) ES2145978T3 (sh)
GR (1) GR3033729T3 (sh)
HU (1) HU225716B1 (sh)
IL (1) IL124415A (sh)
MX (1) MX9803791A (sh)
MY (1) MY118946A (sh)
NO (1) NO310195B1 (sh)
NZ (1) NZ323282A (sh)
PE (1) PE17998A1 (sh)
PL (1) PL184728B1 (sh)
PT (1) PT776899E (sh)
TR (1) TR199800876T2 (sh)
TW (1) TW371661B (sh)
UA (1) UA56145C2 (sh)
WO (1) WO1997019080A1 (sh)
YU (1) YU49316B (sh)
ZA (1) ZA969645B (sh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1070068B2 (en) * 1998-03-13 2007-01-17 The University Of British Columbia Granulatimide derivatives for use in cancer treatment
CA2245029A1 (en) 1998-03-13 1999-09-13 University Of British Columbia Granulatimide compounds as g2 checkpoint inhibitors
US6127401A (en) * 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6300106B1 (en) 2000-11-22 2001-10-09 Ppg Industries Ohio, Inc. Method of preparing 3-[2-{(Methylsulfonyl)oxy}-ethoxy ]-4-(triphenylmethoxy)-1-butanol, methane sulfonate
EP2181999A1 (en) 2008-11-03 2010-05-05 Zentiva, A.S. Method of manufacturing ruboxistarin
WO2023192984A1 (en) * 2022-03-31 2023-10-05 4M Therapeutics Inc. N-desmethyl ruboxistaurin as kinase inhibitor
WO2024159211A1 (en) * 2023-01-27 2024-08-02 Mellicell, Inc. Methods and compositions for treatment of obesity and diseases associated with fat cell enlargement

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT93947B (pt) * 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
US5624949A (en) * 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
UA44690C2 (uk) * 1993-12-07 2002-03-15 Елі Ліллі Енд Компані Макроциклічна сполука іміду біс-індол-малеїнової кислоти, спосіб її одержання та фармацевтична композиція, макроциклічні сполуки іміду біс-індол-малеїнової кислоти та біс-індол-малеїнового ангідриду, спосіб одержання (варіанти)
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides

Also Published As

Publication number Publication date
MY118946A (en) 2005-02-28
DE69607443T2 (de) 2000-08-10
DE69607443D1 (de) 2000-05-04
IL124415A (en) 2003-11-23
KR19990067600A (ko) 1999-08-25
BR9611709A (pt) 1999-02-23
EA199800368A1 (ru) 1998-12-24
HUP9901975A3 (en) 2000-01-28
TR199800876T2 (xx) 1998-08-21
CA2237401C (en) 2003-10-21
AU7738896A (en) 1997-06-11
CZ150398A3 (cs) 1998-12-16
IL124415A0 (en) 1998-12-06
DK0776899T3 (da) 2000-07-10
EP0776899A1 (en) 1997-06-04
MX9803791A (es) 1998-09-30
WO1997019080A1 (en) 1997-05-29
AU701659B2 (en) 1999-02-04
CN1207740A (zh) 1999-02-10
PT776899E (pt) 2000-08-31
NO982105L (no) 1998-05-08
ZA969645B (en) 1998-05-18
NZ323282A (en) 1999-01-28
CA2237401A1 (en) 1997-05-29
YU49316B (sh) 2005-06-10
AR004719A1 (es) 1999-03-10
ES2145978T3 (es) 2000-07-16
PE17998A1 (es) 1998-04-20
GR3033729T3 (en) 2000-10-31
KR100342142B1 (ko) 2002-08-22
JP2008138006A (ja) 2008-06-19
UA56145C2 (uk) 2003-05-15
TW371661B (en) 1999-10-11
JP4100708B2 (ja) 2008-06-11
HU225716B1 (en) 2007-07-30
CN1066734C (zh) 2001-06-06
AR004718A1 (es) 1999-03-10
ATE191219T1 (de) 2000-04-15
NO310195B1 (no) 2001-06-05
PL184728B1 (pl) 2002-12-31
CO4750824A1 (es) 1999-03-31
PL326753A1 (en) 1998-10-26
JP2000500496A (ja) 2000-01-18
EA000639B1 (ru) 1999-12-29
NO982105D0 (no) 1998-05-08
HUP9901975A2 (hu) 1999-11-29
EP0776899B1 (en) 2000-03-29

Similar Documents

Publication Publication Date Title
ES2162843T3 (es) Inhibidores de la proteina quinasa c.
TR199800759T2 (xx) Protein Kinaz C �nhibit�r�.
MX9707431A (es) Inhibidores de la proteina cinasa c.
ES2056699T3 (es) Diaminoftalimidas substituidas y analogos.
CA2219359A1 (en) Hydantoin derivatives as intermediates for pharmaceutical active compounds
YU61096A (sh) Novi intermedijari, njihova primena u sintezi n,n'-premoštenih bisindolilmaleimida i farmaceutske formulacije
DE69330601D1 (de) Serotoninergische ergolin derivate
MX9303605A (es) Derivados de azabicicloheptano n-substituidas, su obtencion y uso.
FI852743A0 (fi) Acetyleniska fenoxipropanolderivat och farmaceutiska kompositioner foer behandling av hypertoni.
ECSP961937A (es) Inhibidor de proteina quinasa "c"